Role of P-selectin in thromboembolic events in patients with cancer
- PMID: 29387414
- PMCID: PMC5769283
- DOI: 10.3892/mco.2017.1482
Role of P-selectin in thromboembolic events in patients with cancer
Abstract
The objective of the present study was to evaluate the role of P-selectin in patients with cancer with suspected thromboembolic events (TEEs). Patients with cancer have a four times greater risk of developing TEEs. P-selectin is a glycoprotein that has the function of facilitating the interaction (adhesion) of leukocytes with the endothelium, or with platelets. There is a well-defined relationship between P-selectin and thrombosis; however, it is likely that the cut-off value of P-selectin for patients with cancer should be considered differently from that of the general population. In the present report, a prospective cross-sectional study was performed with patients of the Cancer Hospital of Barretos who were suspected of having TEEs. Among the 178 study participants, 167 (93.82%) were suspected of having deep vein thrombosis, while 59 of them (35.33%) were confirmed as such; and 11 (6.18%) were suspected of having pulmonary thromboembolism, while 3 of them were confirmed as such (27.69%). The mean results obtained were: P-selectin, 25.37 ng/ml; and D-dimer, 2,181.22 ng/ml. The P-selectin levels averaged 33.60 ng/ml with the confirmed TEE group compared with 20.40 ng/ml with the unconfirmed TEE group, with a standard deviation of 23.35 compared with 6.92 (P<0.001); and the level of D-dimer was 4,615.38 ng/ml compared with 977.52 ng/ml, with a standard deviation of 6,460.54 compared with 2,145.50 (P<0.001). Multiple logistic regression adjusted for distant metastases and the Eastern Cooperative Oncology Group (ECOG) score (2,3 and 4) were constructed. The cut-off value of P-selectin for patients with cancer was identified to be different from that reported in the literature for the general population, and the models using D-dimer and P-selectin therefore have been demonstrated to be a potentially useful tool to be used in a panel of tests to predict TEEs, either independently or in a prediction score.
Keywords: D-dimer; P-selectin; thromboembolism; thrombosis.
Similar articles
-
Markers of Thrombin Generation and Inflammation in Patients with Paroxysmal Nocturnal Hemoglobinuria.Indian J Hematol Blood Transfus. 2021 Apr;37(2):204-209. doi: 10.1007/s12288-019-01239-x. Epub 2019 Nov 26. Indian J Hematol Blood Transfus. 2021. PMID: 33867725 Free PMC article.
-
Could a D-dimer/fibrinogen ratio have a role in ruling-out venous thromboembolism?Emerg Med J. 2022 Dec;39(12):941-944. doi: 10.1136/emermed-2020-210688. Epub 2021 Sep 7. Emerg Med J. 2022. PMID: 34493596
-
Comparison of diverse platelet activation markers as indicators for left atrial thrombus in atrial fibrillation.Platelets. 2018 Jan;29(1):41-47. doi: 10.1080/09537104.2017.1293805. Epub 2017 Mar 13. Platelets. 2018. PMID: 28287031
-
A critical appraisal of non-invasive diagnosis and exclusion of deep vein thrombosis and pulmonary embolism in outpatients with suspected deep vein thrombosis or pulmonary embolism: how many tests do we need?Int Angiol. 2005 Mar;24(1):27-39. Int Angiol. 2005. PMID: 15876996 Review.
-
[P-selectin and its role in some diseases].Postepy Hig Med Dosw (Online). 2009 Oct 19;63:465-70. Postepy Hig Med Dosw (Online). 2009. PMID: 19850970 Review. Polish.
Cited by
-
Soluble P-selectin level in patients with cancer-associated venous and artery thromboembolism: a systematic review and meta-analysis.Arch Med Sci. 2023 Jan 13;19(1):274-282. doi: 10.5114/aoms/159039. eCollection 2023. Arch Med Sci. 2023. PMID: 36817657 Free PMC article. No abstract available.
-
A pilot study of procoagulant platelet extracellular vesicles and P-selectin increase during induction treatment in acute lymphoblastic leukaemia paediatric patients: two new biomarkers of thrombogenic risk?J Thromb Thrombolysis. 2021 Apr;51(3):711-719. doi: 10.1007/s11239-020-02346-7. Epub 2020 Nov 28. J Thromb Thrombolysis. 2021. PMID: 33247807
-
Von Willebrand factor:antigen and ADAMTS-13 level, but not soluble P-selectin, are risk factors for the first asymptomatic deep vein thrombosis in cancer patients undergoing chemotherapy.Thromb J. 2020 Nov 11;18(1):33. doi: 10.1186/s12959-020-00247-6. Thromb J. 2020. PMID: 33292287 Free PMC article.
-
Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer.JCI Insight. 2019 Feb 21;4(4):e125851. doi: 10.1172/jci.insight.125851. eCollection 2019 Feb 21. JCI Insight. 2019. PMID: 30652973 Free PMC article. Clinical Trial.
-
Thromboinflammatory Biomarkers in Lymphomas: Linking Inflammation to Thrombosis Risk.Int J Mol Sci. 2025 Feb 26;26(5):2058. doi: 10.3390/ijms26052058. Int J Mol Sci. 2025. PMID: 40076681 Free PMC article.
References
-
- Huth EJ, Murray TJ. Medicine in Quotations: Views of Health and Disease Through the Ages. American College of Physicians, Philadelphia. 2006
-
- Anderson FA, Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: The Worcester DVT Study. Arch Intern Med. 1991;151:933–938. doi: 10.1001/archinte.1991.00400050081016. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources